ArticleInternational ophthalmology2025
Interferon alpha-2b versus 5-fluorouracil as primary treatment modalities for ocular surface squamous neoplasia: a study of 116 eyes.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Formulation of treatment protocol for ocular surface squamous neoplasia.International ophthalmology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the efficacy and side-effect profile of interferon alpha-2b (IFNα2B) and topical 5-fluorouracil (5-FU) as primary treatment modalities for ocular surface squamous neoplasia (OSSN).
methodsRetrospective comparative study of 116 OSSN eyes treated with topical 1 MIU IFNα2B with/without 5 MIU/cc subconjunctival injection (group 1) or topical 1% 5-FU (group 2) in mutually exclusive time periods of treatment.
resultsOf the 116 eyes with OSSN, 64 eyes belonged to group 1 and 52 eyes to group 2. The mean tumor basal conjunctival diameter for groups 1 and 2 was 10 mm (median, 10 mm; range 0-28 mm) and 5 mm (median, 4 mm; range, 0-24 mm) respectively (p < 0.0001). Complete tumor regression with medical management alone was achieved in 51 (80%) eyes in group 1 and 43 (83%) eyes in group 2 (p = 0.6814). The mean number of sessions/cycles of treatment for complete tumor regression was 3 (median, 3; range, 1-6) for group 1 versus 2 (median, 2; range, 1-6) for group 2 (p < 0.0001). Tumor recurrence was noted in 3 (5%) eyes in group 1 over a mean follow-up period (months) of 11 (median, 7; range, 3-41) versus 1 (2%) in group 2 (p = 0.25) over a mean follow-up period (months) of 6 (median, 5; range, 1-25). Side-effects included transient conjunctival hyperemia (9%), and flu-like symptoms (3%) in group 1 versus transient conjunctival hyperemia (2%), punctal stenosis (2%), and partial limbal stem cell deficiency (2%) in group 2.
conclusionPrimary treatment of OSSN with IFNα2b or 5-FU offers comparable and good tumor control with minimal side-effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.